Several papers have mentioned the possibility of anti-HBV and anti-HCV drugs that influence HNF4α levels; however, their use may lead to worse clinical outcomes, as HNF4α is an important factor in HCC. The gene discussed is HNF4A; the disease is hepatocellular carcinoma.